Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. [electronic resource]
Producer: 20090714Description: 3842-9 p. digitalISSN:- 1538-7445
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Cell Growth Processes -- drug effects
- Colonic Neoplasms -- blood supply
- Dasatinib
- Down-Regulation
- Drug Synergism
- HCT116 Cells
- HT29 Cells
- Humans
- Liver Neoplasms, Experimental -- drug therapy
- Male
- Mice
- Mice, Nude
- Neovascularization, Pathologic -- drug therapy
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Oxidative Stress -- drug effects
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Random Allocation
- Reactive Oxygen Species -- metabolism
- Thiazoles -- administration & dosage
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- src-Family Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.